GTBP
GT Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.16
−4.41%Sep 15, 2026, 13:15 UTC
GT Biopharma received FDA clearance of a new IND for GTB-5550 in multiple myeloma under an investigator-sponsored trial protocol.
Source:Sep 15, 2026, 13:02 UTC
GT Biopharma, Inc. directors and officers signed a Lock-Up Agreement not to sell or transfer any securities of the Company until 30 days after the later of the Effective Date and the date Shareholder Approval is obtained.
Sep 15, 2026, 13:02 UTC
GT Biopharma, Inc. officers and directors signed a Voting Agreement to vote all shares of voting stock under their control in favor of a proposal seeking Shareholder Approval for issuance of more than 19.99% of the Company's outstanding Common Stock.
Sep 15, 2026, 13:02 UTC
GT Biopharma, Inc. signed a Registration Rights Agreement with the Purchasers to file an SEC registration statement covering resale of common stock issuable upon conversion of the preferred stock and exercise of the warrants.
Sep 15, 2026, 13:02 UTC
GT Biopharma, Inc. signed a Securities Purchase Agreement to issue and sell up to 8,277.778 shares of Series M 10% Convertible Preferred Stock and warrants to purchase common stock, with an aggregate stated value of $8,277,778 for an aggregate purchase price of $7,450,000, in a private placement.
Sep 11, 2026, 12:00 UTC
GT Biopharma will host a live company presentation on the development of its TriKE natural killer cell engager platform for cancer treatment on September 11, 2026.
Source:Aug 14, 2026, 12:00 UTC
GT Biopharma reported its financial results for the second quarter of 2026.
Source: